Pancramin
Pancreas cytamin — Khavinson-school organ peptide fraction, oral tablet
Pancramin (Pancreas cytamin — Khavinson-school organ peptide fraction, oral tablet) is a longevity & bioregulators research compound. A polypeptide fraction extracted from animal pancreas, 155mg per tablet. The pancreas is the one organ in this line where the school published a result in a large animal: the synthetic tetrapeptide pancragen was reported to change endocrine pancreatic function in old monkeys. That is a different substance — a defined four-amino-acid peptide rather than an undefined tissue fraction — and it makes the comparison this page can draw sharper than most, because the endpoint it moved is the endpoint anyone can measure for about thirty dollars.
Pancramin quick facts
| Route | Oral |
| Frequency | Not established · Not established |
| Half-life | Not characterized — no analytical method for this preparation has been published |
| Forms | Oral |
| Evidence level | No published study of this product. The pancreatic result in this school belongs to a synthetic tetrapeptide tested in monkeys. |
Of every tablet in this line, this is the one where the missing experiment is most obviously worth running: fasting glucose, HbA1c and fasting insulin are standardized worldwide, cost less than one pack, and are exactly what the school's own monkey study measured for the synthetic peptide. Nobody has ever reported one of them for this product, and a search for its name on 8 September 2026 returned zero records.
How Pancramin works
A polypeptide fraction extracted from animal pancreas, 155mg per tablet. The pancreas is the one organ in this line where the school published a result in a large animal: the synthetic tetrapeptide pancragen was reported to change endocrine pancreatic function in old monkeys. That is a different substance — a defined four-amino-acid peptide rather than an undefined tissue fraction — and it makes the comparison this page can draw sharper than most, because the endpoint it moved is the endpoint anyone can measure for about thirty dollars.
Proposed benefits
Researched for mitochondrial and cellular-energy support, tissue-specific bioregulation and healthy-aging pathways.
Where to get Pancramin
Buy Pancramin at RUPharma →The evidence for Pancramin
Graded by what exists behind each claim.
✅ Clinically validated
- None. A PubTator3 search of PubMed for this product's name, run 8 September 2026, returned zero records — no trial, no case series, no pharmacokinetic study, no adverse event report. That zero is the finding, and it is not the same as a trial having been run and failed. The measurements that would settle it are ordinary: fasting glucose, fasting insulin and HbA1c are standardized worldwide and cost less than one 40-tablet pack.
📊 Correlative data
- The strongest animal result anywhere in the organ-peptide catalog is the synthetic tetrapeptide pancragen changing endocrine pancreatic function in old monkeys (Goncharova 2014). A defined four-residue peptide, a primate, an endocrine endpoint — and not this product.
- Pancreas was one of the four organs in the organotypic explant work (Zakutskii 2006), and calf-tissue polypeptides were applied to matching cultures at 0.01-100 ng/ml (Ryzhak 2015).
- The one human paper naming this class in an athletic population is a 2004 Russian combination study of cytamines with ecdystene, apilak, vitamax and essentiale on work capability (Emirova 2004). A combination study; no single organ product isolated.
🧪 Theoretical / extrapolated
- The organ this tablet is named after makes the enzymes that destroy it. Trypsin, chymotrypsin and elastase are pancreatic products secreted into the duodenum, and their job is to reduce swallowed protein to fragments.
- Fasting glucose, fasting insulin and C-peptide are standardized worldwide, cost less than a pack, and are the human version of the endpoint the monkey study used. None has been reported for this product.
How to read these tiers: they say how much human evidence exists, not how well something works — and ✗ flags harm, never a disappointing trial. How the evidence tiers work →
What Pancramin actually does
The organ this tablet is named after makes the enzymes that destroy it. That is not a rhetorical flourish, it is the pharmacology: trypsin, chymotrypsin, elastase and carboxypeptidase are pancreatic products, they are secreted into the duodenum, and their job is to reduce swallowed protein to fragments. A 155 mg nucleoprotein tablet of pancreatic tissue meets the pancreas's own proteases before it meets anything else. Every oral organ extract faces this; only this one faces it from the organ on the label.
The pancreas is where this school produced its single best animal result, and it used a different molecule. Goncharova 2014 reports the effect of the synthetic tetrapeptide pancragen on endocrine pancreatic function in old monkeys. A defined four-residue peptide, a primate, an endocrine endpoint. That is the most translationally serious experiment anywhere in the organ-peptide catalog, and the product being sold here is not what was tested.
The explant work included pancreas, which most organs in this line cannot say. Zakutskiĭ 2006 applied synthetic peptide bioregulators including pancragen to organotypic cultures of heart, lung, prostate and pancreas from young and old rats and reported tissue-matched effects on the growth zone. Ryzhak 2015 did the equivalent with calf-tissue polypeptides at 0.01 to 100 ng/ml. Both are dishes.
The class claim, and the specific thing it would have to mean here. The premise is tissue-specific regulation of gene expression by peptides released from an organ fraction Khavinson 2021. For a pancreas product that has to mean a change in beta cell function, insulin secretion or insulin sensitivity, because those are what endocrine pancreatic function is. All three are measurable in an outpatient laboratory for less than the price of a pack, and none has ever been reported for this tablet.
Cell, rodent, human — and where it stops
The search, and the date. A PubTator3 query of PubMed for pancramin, run 8 September 2026, returned zero records. Not a small literature — none. Every citation on this page is about a different preparation, and the sentences name it.
What the monkey study says and what it does not. Goncharova 2014 is a report of pancragen changing endocrine pancreatic function in old monkeys. Pancragen is a synthetic tetrapeptide of defined sequence, manufactured to a specification, administered to a primate. Pancramin is an undefined fraction of ground pancreas pressed into a tablet. Reading across from the first to the second requires assuming that the fraction contains the tetrapeptide, that enough of it survives digestion, and that a monkey result transfers to a person. Those are three assumptions and the market treats them as none.
The one human paper that names the class in this readership. Emirova 2004 is a 2004 Russian pharmacology paper on cytamines and their combinations with ecdystene, apilak, vitamax and essentiale on the work capability of athletes. It is the closest thing to a performance study this shelf has. It is a combination study, its abstract reports that cytamine formulations improved exercise tolerance and potentiated the other agents, and the three cytamins it names are hepatamin, epifamin and suprenamin — liver, pineal and adrenal. No pancreas tablet appears in it. Reported here because it exists and because the pages built before this batch did not find it.
Where the chain breaks. The rungs that exist are: defined synthetic peptide in a primate, defined synthetic peptide on rat explants, tissue polypeptide preparation on rat explants at nanogram concentrations, and a Russian combination study in athletes that does not name this product. The rung that does not exist is the one this product needs: anything at all, in anyone, after swallowing this tablet.
Pancramin pharmacokinetics — how much of it actually gets in
What degrades it — and here the answer has a name. Gastric acid and pepsin denature and cleave; then pancreatic trypsin, chymotrypsin and elastase, secreted into the duodenum, cut the remainder at basic, aromatic and small hydrophobic residues respectively; then brush-border peptidases hydrolyze what is left to amino acids and di- and tripeptides. There is no enteric coating claimed, no dissolution profile published, and no protease-resistance data for this preparation.
The oral barrier, and the number that makes it concrete. Adult pancreatic exocrine output is on the order of 6 to 20 grams of enzyme protein per day into the small intestine. A 155 mg tablet is under 3% of a single day's proteolytic output by mass, arriving into the middle of it. Whatever intact peptide crosses the enterocyte does so through saturable carriers built for two- and three-residue fragments.
The comparator, and why it changes the argument. Goncharova 2014 gave a defined peptide to monkeys, and the school's peptide preparations are administered by injection when an effect is being demonstrated rather than sold. An injected route starts with the whole dose in blood. This tablet starts behind the gut wall, behind the pancreas's own enzymes, with no published measurement of what emerges. That is why no half-life can be quoted for it: there is no analytical method, therefore no analyte, therefore no curve.
What is knowable about timing. A protein load raises plasma amino acids for two to four hours and returns to baseline. Any pharmacology from this product would follow that shape, which means the honest framing of a 40-tablet course is forty separate brief exposures rather than a level that builds. Nothing about the packaging or the price implies otherwise, and nothing about the pharmacology supports a cumulative claim.
What would have to be true, and how you would know it was not
Four predictions. This is the cheapest page on the shelf to prove wrong, which is why the list is specific.
1. Fasting glucose and fasting insulin, baseline and end of pack. Two numbers, drawn at the same time, from one tube. They give HOMA-IR arithmetic for free and they are exactly what endocrine pancreatic function means in a person. Zero published records of this tablet report either. Prediction: neither moves.
2. HbA1c, baseline and twelve weeks. A 40-tablet pack is too short for HbA1c to be a fair test, which is itself the useful point — the marker reflects roughly three months of glycemia, so a single course cannot move it and a claim that it did would be a claim about something else. Anyone running this properly needs two packs and twelve weeks.
3. C-peptide is the marker that would make this interesting. It measures endogenous insulin secretion specifically, and it is the human version of the endpoint the monkey study used Goncharova 2014. If a pancreas extract raised beta cell output, C-peptide is where it would show. Prediction: flat, and the prediction is worth stating because the measurement has never been made.
4. Against the product, sharply. If this tablet did move insulin secretion, it would be a drug rather than a supplement, and it would carry a hypoglycemia risk in anyone already taking a sulfonylurea or insulin. The market wants the effect and none of the consequence. Either it does nothing measurable, or it needs the monitoring that anything affecting glucose needs, and there is no third option.
What nobody has tested yet
Nobody has run the oral glucose tolerance test. Two hours, one standardized drink, four draws. It is the oldest and most informative test of pancreatic endocrine function in existence, it costs less than a pack of these tablets, and it has never been reported for any product in the cytamin line.
Nobody has compared the extract with the synthetic peptide. The same catalog sells pancragen, the tetrapeptide with the monkey study Goncharova 2014, and pancramin, the extract with nothing. A head-to-head on any shared endpoint would be the first comparison ever published between two products in this family, and it is the comparison a vendor selling both has the least incentive to fund.
Nobody has assayed a tablet for hormone content. Pancreatic tissue contains insulin and glucagon. Whether a finished tablet retains any measurable hormone activity after processing is a straightforward immunoassay question with no published answer, and it is the question that would matter most if the answer were not zero.
Extrapolation, labeled as such. If the active principle is a short peptide that survives digestion, then it should be findable in plasma, reproducible synthetically, and independent of the tissue it came from. Ryzhak 2003 shows the school runs analytical work on its own manufacturing. Turning that instrument on a finished pack is the missing step, and it is a week of laboratory time rather than a research program.
Pancramin — its own safety story, not its class's
Three things specific to an oral extract of animal pancreas.
The absent adverse-event record and what it measures. Zero published studies means zero published adverse events, and those two zeros are the same zero. No setting has existed in which a side effect of this product could have been recorded, so the blank column describes the literature rather than the tablet.
The hypothetical that deserves naming. Pancreatic tissue contains insulin. Nobody has published an assay of a finished tablet, so nobody can say whether any hormone activity survives manufacturing — and the honest expectation is that oral insulin is destroyed by digestion, which is why insulin is injected. The reason to write this down anyway is that a comparable glandular category was found to carry measurable hormone when somebody finally looked, and the equivalent look has never been taken at this one.
Anyone managing blood sugar with a prescribed medicine has no data here. There is no interaction study between this tablet and metformin, a sulfonylurea, a GLP-1 receptor agonist or insulin. The class of reader most drawn to a pancreas product is the class of reader for whom an unmeasured glucose effect would matter most, and that combination belongs in front of the prescriber who manages the medicine rather than on a product page.
Sources read for this page
- Goncharova ND, Ivanova LG, Oganian TÉ, Vengerin AA, Khavinson VKh. Impact of tetrapeptide pancragen on endocrine function of the pancreas in old monkeys. Advances in Gerontology 2014;27(4):662–667 · PMID 25946840
- Zakutskiĭ AN, et al. The tissue-specific effect of synthetic peptides-biologic regulators in organotypic tissues culture in young and old rats. Advances in Gerontology 2006 · PMID 17152728
- Ryzhak AP, Chalisova NI, Lin'kova NS, Khalimov RI, Ryzhak GA, Zhekalov AN. [Polypeptides influence on tissue cell cultures regeneration of various age rats]. Advances in Gerontology 2015;28(1):97-103 [Russian] · PMID 26390619
- Emirova LR, Rozhkova EA, Paniushkin VV, Mirzoian RS, Seifulla NR. [The effects of cytamines and their combinations with ecdystene, apilak, vitamax, and essentiale on the work capability of athletes]. Eksperimental'naia i Klinicheskaia Farmakologiia 2004 [Russian] · PMID 15341074
- Ryzhak GA, Nekrasov PA, Kiselev OI, Khavinson VKh. Study of protein components of natural peptide regulators. Bulletin of Experimental Biology and Medicine 2003 · PMID 12717513
- Khavinson VKh, Popovich IG, Linkova NS, Mironova ES, Ilina AR. Peptide Regulation of Gene Expression: A Systematic Review. Molecules 2021;26(22):7053 · PMID 34834147
- Khavinson VKh, Cherniak SI, D'iakonov MM. [Cytamines--preparations for maintaining high professional ability and longevity in servicemen]. Voenno-Meditsinskii Zhurnal 2001 [Russian] · PMID 11338817
Pancramin — safety, predicted from mechanism
Predicted from mechanism, not from a human safety trial. How that reasoning works →
What the mechanism predicts
Derived from the molecule, not a trial.
- These are short peptide fragments of organ extracts, and the honest starting point is that the mechanism itself is not established in a way that lets anyone predict harm precisely. The proposal is gene-regulatory — short peptides binding DNA and modulating transcription in a tissue-specific way. If that is what they do, the theoretical concern is influencing transcription in tissue you were not aiming at.
- In practice the doses are tiny, the peptides are short, and they are degraded quickly — which is also the argument that they may do very little at all. Those two possibilities are the same uncertainty viewed from opposite ends, and you should hold both.
What has actually been reported
- Decades of Russian clinical use with a strikingly clean tolerability record — injection-site reactions and little else reported.
- That record comes almost entirely from one research school, is largely unreplicated outside it, and safety data from a group with an interest in the outcome is worth less than the same data from a skeptic. This is not an accusation; it is how evidence weighting works.
How to reduce the risk
Same mechanism as the prediction.
- Follow the course printed on the label rather than running continuously. These are the one class in the Vault where a duration is STATED rather than inferred, and it is typically 10–20 days repeated a few times a year. Read the box.
- Run one at a time. They are cheap and it is tempting to stack six. If something changes, a stack of six tells you nothing about which one did it — and given the evidence base, attribution is the entire value of your own experiment.
- Decide your endpoint before you start, and make it a marker or a measurable symptom rather than a feeling. With a compound class this under-evidenced, an unfalsifiable endpoint means you will conclude it worked no matter what happened.
- Buy from a source that publishes third-party testing. Where the molecule itself is uncertain, identity and purity are the only variables you can actually control.
What it does to your bloodwork
A fact about the assay.
- Test the ORGAN, not the peptide. A thymic peptide is judged on immune markers, a pineal one on sleep and IGF-1, a vascular one on lipids and inflammatory markers. There is no assay for the compound itself.
Don't run this if
- Pregnancy — not because of a specific finding, but because nobody has studied it and the mechanism claim is transcriptional.
- Active malignancy, on the same reasoning as any tissue-growth signal: unproven, mechanistically arguable, and not worth finding out.
The honest unknown
- Essentially everything a skeptic would want: independent replication, pharmacokinetics, and whether the oral forms survive digestion at all. Unproven is not the same as ineffective — but here it is a large unproven.
Not medical advice. If you take prescription medication or have a diagnosed condition, check this with a pharmacist or doctor.
Pancramin — interference & stacking
Predicted from mechanism, not from an interaction study. How mechanism-predicted claims are made →
What Pancramin moves on your bloodwork
Expected direction, not a measured one.
- Comprehensive Metabolic Panel (CMP) — ◆ worth watching
These are short peptide fragments given in microgram amounts and there is no mechanism predicting a specific marker shift. Listing markers here would be padding.
What to do: Test the organ system the bioregulator is aimed at, not a generic panel — that is the only measurement that would tell you anything.
The evidence base here is almost entirely one research group's, largely in Russian, and rarely replicated independently. That is the single most important thing to know before running a course, and it is more useful than any interaction list.
- Dose range and how to work up to it
- When to take it, and why that window
- Cycle length
- Time off between cycles
- Fasted or fed, and when in the day
- Coach Cam's personal notes
- Which compounds push the same lever, and why the dose adds up faster than people count
- What blunts it — the stacks that waste your money
- What compounds the risk, so a side effect arrives sooner than any one of them suggests
- Coach Cam's read on running it alongside the rest of your protocol
Everything above is free and stays free. Skool is where it becomes a plan — Pancramin in an order, with the rest of what you're running.
Unlock in Skool — $10/mo →Bloodwork to run alongside Pancramin
Baseline first, then again at 8–12 weeks.
| Marker | What it’s watching for |
|---|---|
| hs-CRP (High-Sensitivity C-Reactive Protein) | Chronic low-grade inflammation is the process most of these target |
| ApoB (Apolipoprotein B) | Counts the particles that actually cause plaque, unlike LDL-C |
| HbA1c (Hemoglobin A1c) | Glycation, which is the other half of the ageing story |
| Comprehensive Metabolic Panel (CMP) | Liver and kidney — the two organs that clear everything you take |
| Complete Blood Count (CBC) with Differential | The cheapest broad screen there is |
The Longevity Baseline panel covers these in one order — 13 markers, $219.10 with the discount applied.
Check results you already have → · All 103 markers A–Z
Pancramin — frequently asked questions
What is Pancramin?
Pancramin (Pancreas cytamin — Khavinson-school organ peptide fraction, oral tablet) is a longevity & bioregulators research compound. A polypeptide fraction extracted from animal pancreas, 155mg per tablet. The pancreas is the one organ in this line where the school published a result in a large animal: the synthetic tetrapeptide pancragen was reported to change endocrine pancreatic function in old monkeys. That is a different substance — a defined four-amino-acid peptide rather than an undefined tissue fraction — and it makes the comparison this page can draw sharper than most, because the endpoint it moved is the endpoint anyone can measure for about thirty dollars.
Where can I find Pancramin dosing and protocols?
Dosing, the reconstitution calculator and Coach Cam's full Pancramin protocol are available to members inside Skool. This public page covers what Pancramin is, how it works and the evidence.
What is the half-life of Pancramin?
Pancramin has an approximate half-life of Not characterized — no analytical method for this preparation has been published, which is part of what determines how often it's dosed.
What's the evidence behind Pancramin?
Current evidence level: No published study of this product. The pancreatic result in this school belongs to a synthetic tetrapeptide tested in monkeys.. Pancramin is offered for research purposes only and is not an approved medicine.
What Pancramin is used for
Pancramin appears under 1 goal in the goal router.
Related Longevity & Bioregulators compounds
Where this goes next
The pages here are the frameworks. The protocols — the dosing, the order to correct things in, the week-by-week schedule and what to retest — are inside Skool.